Zacks: Brokerages Expect Aduro Biotech, Inc. (ADRO) to Announce -$0.36 EPS

Wall Street brokerages expect Aduro Biotech, Inc. (NASDAQ:ADRO) to report earnings per share of ($0.36) for the current quarter, according to Zacks. Three analysts have made estimates for Aduro Biotech’s earnings. The highest EPS estimate is ($0.31) and the lowest is ($0.41). Aduro Biotech posted earnings of $0.03 per share in the same quarter last year, which would indicate a negative year-over-year growth rate of 1,300%. The business is expected to announce its next earnings report on Wednesday, August 2nd.

On average, analysts expect that Aduro Biotech will report full year earnings of ($1.46) per share for the current fiscal year, with EPS estimates ranging from ($1.67) to ($1.30). For the next year, analysts expect that the firm will report earnings of ($1.41) per share, with EPS estimates ranging from ($1.89) to ($0.85). Zacks’ earnings per share calculations are a mean average based on a survey of research analysts that follow Aduro Biotech.

Aduro Biotech (NASDAQ:ADRO) last posted its quarterly earnings results on Tuesday, May 2nd. The biotechnology company reported ($0.32) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.39) by $0.07. Aduro Biotech had a negative return on equity of 35.35% and a negative net margin of 166.85%. The company had revenue of $3.77 million for the quarter, compared to analysts’ expectations of $3.74 million.

A number of equities analysts have issued reports on ADRO shares. Canaccord Genuity set a $30.00 price target on Aduro Biotech and gave the stock a “buy” rating in a research report on Monday, March 27th. Zacks Investment Research downgraded Aduro Biotech from a “hold” rating to a “strong sell” rating in a research report on Tuesday, May 2nd. Rodman & Renshaw started coverage on Aduro Biotech in a research report on Monday, May 1st. They set a “buy” rating and a $18.00 price target on the stock. HC Wainwright started coverage on Aduro Biotech in a research report on Monday, May 1st. They set a “buy” rating and a $18.00 price target on the stock. Finally, Cowen and Company started coverage on Aduro Biotech in a research report on Tuesday, July 18th. They set an “outperform” rating on the stock. Eight analysts have rated the stock with a buy rating, Aduro Biotech presently has a consensus rating of “Buy” and an average price target of $19.00.

In other news, EVP Dirk G. Brockstedt sold 8,000 shares of the firm’s stock in a transaction that occurred on Thursday, May 11th. The stock was sold at an average price of $9.72, for a total value of $77,760.00. Following the transaction, the executive vice president now owns 57,300 shares in the company, valued at $556,956. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Thomas W. Dubensky sold 50,000 shares of the firm’s stock in a transaction that occurred on Thursday, July 6th. The shares were sold at an average price of $11.33, for a total value of $566,500.00. Following the completion of the transaction, the insider now owns 51,700 shares in the company, valued at approximately $585,761. The disclosure for this sale can be found here. Insiders have sold 419,205 shares of company stock worth $4,410,591 in the last quarter. 6.60% of the stock is currently owned by company insiders.

Several large investors have recently bought and sold shares of ADRO. Bank of New York Mellon Corp boosted its stake in Aduro Biotech by 3.8% in the first quarter. Bank of New York Mellon Corp now owns 148,166 shares of the biotechnology company’s stock valued at $1,593,000 after buying an additional 5,470 shares in the last quarter. Quantitative Systematic Strategies LLC acquired a new stake in Aduro Biotech during the first quarter valued at about $145,000. Fox Run Management L.L.C. acquired a new stake in Aduro Biotech during the first quarter valued at about $202,000. Daiwa SB Investments Ltd. acquired a new stake in Aduro Biotech during the first quarter valued at about $153,000. Finally, Creative Planning boosted its stake in Aduro Biotech by 73.9% in the first quarter. Creative Planning now owns 15,000 shares of the biotechnology company’s stock valued at $161,000 after buying an additional 6,375 shares during the period. 35.65% of the stock is owned by hedge funds and other institutional investors.

ILLEGAL ACTIVITY WARNING: This story was reported by [[site]] and is the sole property of of [[site]]. If you are accessing this story on another publication, it was copied illegally and reposted in violation of U.S. and international trademark and copyright legislation. The original version of this story can be viewed at [[permalink]].

Aduro Biotech (NASDAQ:ADRO) traded up 0.36% on Tuesday, reaching $13.75. The company had a trading volume of 244,258 shares. The stock’s market capitalization is $961.30 million. Aduro Biotech has a 1-year low of $8.75 and a 1-year high of $16.43. The stock’s 50 day moving average is $11.45 and its 200-day moving average is $10.85.

Aduro Biotech Company Profile

Aduro Biotech, Inc is an immunotherapy company, which focuses on the discovery, development and commercialization of therapies that manage the treatment of various diseases, including cancer. The Company’s product candidates from its Live, Attenuated, Double-Deleted (LADD) Listeria monocytogenes, Stimulator of Interferon Genes Pathway Activator, and B-select monoclonal antibody platforms are designed to stimulate and/or regulate innate and adaptive immune responses, either as single agents or in combination with conventional therapies, as well as other immunotherapies.

Get a free copy of the Zacks research report on Aduro Biotech (ADRO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com